Orbas Plus 20/12.5: Each film-coated tablet contains Olmesartan Medoxomil INN 20 mg and Hydrochlorothiazide BP 12.5 mg.
ORBAS PLUS 20/12.5 is a combination drug of an angiotensin II receptor antagonist (AT1 subtype), Olmesartan medoxomil, and a thiazide diuretic, Hydrochlorothiazide. Olmesartan medoxomil, a prodrug, is hydrolyzed to olmesartan during absorption from the gastrointestinal tract. It blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor. Thiazides affect the renal tubular mechanisms of electrolytes reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts.
ORBAS PLUS 20/12.5 is indicated for the treatment of hypertension.
Hypertension: The usual starting dose of ORBAS PLUS 20/12.5 is one tablet once daily. Depending on the blood pressure response, the dose may be titrated at intervals of 2-4 weeks to two tablets of ORBAS PLUS 20/12.5 once daily.
Patient with Renal impairment: The usual dose regimens of therapy with ORBAS PLUS 20/12.5 may be followed the patient’s creatinine clearance is > 30 mL/min. In patients with more severe renal impairment, loop diuretics are preferred to thiazides. So, ORBAS PLUS 20/12.5 is not recommended.
Patient with Hepatic impairment: No dosage adjustment is necessary with hepatic impairment.
OR AS DIRECTED BY THE PHYSICIAN.
Olmesartan Medoxomil:
No significant drug interactions were reported in studies in which Olmesartan Medoxomil was co-administrated with Hydrochlorothiazide, Digoxin or Warfarin in healthy volunteers.
Hydrochlorothiazide:
When administered concurrently, the following drugs may interact with Thiazide:
Overdose:Olmesartan Medoxomil:
Limited data are available in regard to over dosage in humans. The most likely manifestation of over dosage would be hypotension and tachycardia. If symptomatic hypotension should occur, supportive treatment should be instituted.
Hydrochlorothiazide:
The most common signs and symptoms observed are those caused by electrolyte depletion (hypokalemia, hypochloremia, and dehydration) resulting from excessive. If, digitalis has also been administered, hypokalemia may accentuate cardiac arrhythmias.
Not recommended.
Safety and effectiveness in pediatric patients (< 18 years of age) have not been established.
Clinical studies of Olmesartan Medoxomil and Hydrochlorothiazide combination did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious.
Store in a cool & dry place, protected from light. Keep all medicines out of reach of children.